<?xml version="1.0" encoding="UTF-8"?>
<p>RSV has long been a target for vaccine development because of its ubiquity and potential for causing severe illness. An overview of RSV vaccines and monoclonal antibodies in development reported 21 candidates in clinical trials [
 <xref rid="CIT0020" ref-type="bibr">20</xref>]. Addressing knowledge gaps about the burden of RSV is crucial to the investment case for these interventions, and their successful future implementation. This study aims to assess the incidence of RSV among young children in Nicaragua, a lower-middle income tropical country in Central America [
 <xref rid="CIT0021" ref-type="bibr">21</xref>]. We used the Nicaraguan Influenza Birth Cohort Study [
 <xref rid="CIT0022" ref-type="bibr">22</xref>], originally designed to examine the incidence of influenza, as it provides a unique opportunity to investigate other respiratory pathogens, such as RSV.
</p>
